Obstetrics and Gynecology
Ashwaq Kadhim Mohammed; Vian Hussam Almansi Alqani; Zainab Muayad Essa
Articles in Press, Accepted Manuscript, Available Online from 09 March 2024
Abstract
Background: An unusual manifestation of prenatal trophoblastic illness is a twin molar pregnancy with a live foetus and a hydatidiform mole. Due to increased ovulation stimulation, this unusual scenario is rising. Most hydatidiform moles are complete with a foetus, while 0.005 to 0.01% of gestations ...
Read More
Background: An unusual manifestation of prenatal trophoblastic illness is a twin molar pregnancy with a live foetus and a hydatidiform mole. Due to increased ovulation stimulation, this unusual scenario is rising. Most hydatidiform moles are complete with a foetus, while 0.005 to 0.01% of gestations have a partial mole. This report examined the clinical appearance and outcome of live foetuses with molar pregnancies. Methods: This study was done at Adiwaniyah, where the Maternity and Pediatrics Teaching Hospital has one obstetrics centre. The researcher reviewed 20 years of obstetric reports and found 12 cases of hydatiform mole pregnancies with ultrasound reports and/or post-partum examination of the product of gestation indicating twin pregnancy with a single viable foetus. Results: The average age was 27.00 ±6.87 years, with a range of 18-37 years. The parity breakdown was 8 (66.7%) primiparous and 4 (33.3%) multiparous. The average gestational age upon diagnosis was 19.50 ±3.09 weeks, ranging from 15 to 25 weeks. The average gestational age at delivery commencement was 26.67 ±7.09 weeks, with a range of 17-35 weeks. Seven (58.3%) amniocentesis were normal. Maternal complications included bleeding, anemia, blood transfusion, threatening miscarriage, and pre-eclampsia. End-of-gestation outcomes comprised 5 (41.7%) living and healthy newborns and 3 (25.0%) dead babies. There were 5 (41.7%) men and 2 (16.7%) women. Also reported: miscarriage, premature labour, and caesarean sections. Conclusion: Twin pregnancy with a live viable foetus and a molar pregnancy is rare, hence early detection and care are crucial to prevent difficulties for the mother and foetus.
Obstetrics and Gynecology
Zainab Muayad Essa; Alia Kareem Mohamad AL-Qarawy; Ashwaq Kadhim Mohammed
Articles in Press, Accepted Manuscript, Available Online from 09 March 2024
Abstract
Background: Endocrine disorders like polycystic ovarian syndrome affect reproductive-age women. It causes infertility and has several clinical symptoms. Clomiphene citrate ovulation induction is a first-line treatment. Serum anti-mullerian hormone can indicate positive pregnancy outcomes in women with ...
Read More
Background: Endocrine disorders like polycystic ovarian syndrome affect reproductive-age women. It causes infertility and has several clinical symptoms. Clomiphene citrate ovulation induction is a first-line treatment. Serum anti-mullerian hormone can indicate positive pregnancy outcomes in women with this disease, however this is controversial. Aim of the study:to assess the value of anti-mullerian hormone (AMH) as an anticipator of ovary response to clomiphene citrate in patients with “polycystic ovary syndrome (PCOS). Patients and methods: A cross-sectional study of 50 women diagnosed with Rotterdam-based polycystic ovarian syndrome by two gynaecologists was conducted. The Maternity and Paediatric Teaching Hospital in Diwaniyah Province, Iraq, conducted the study from August 1, 2022, to May 15, 2023, at the obstetrics and gynaecology department. Women with diabetes or hypertension were excluded from the trial. These women sought medical treatment for infertility and received clomiphene citrate to induce ovulation. The findings of hCG urine and blood testing divided women into positive and negative biochemical pregnancy groups. Results: The mean FSH of all recruited women was 5.19±1.14 IU/L, with no significant difference between pregnant and non-pregnant women (p = 0.849). AMH levels were significantly lower in pregnant women compared to non-pregnant women (p< 0.001). The mean AMH was 6.97±2.88 ng/ml for all enrolled women. ROC curve research determined the optimal AMH cutoff value for predicting positive biochemical pregnancy: ≤6.5 ng/ml with 100% sensitivity, 67.7% specificity, and 80.9 % accuracy. Conclusion: Serum anti-mullerian hormone accurately predicts pregnancy success in PCOS women taking clomiphene citrate to induce ovulation.
